U.S., May 21 -- ClinicalTrials.gov registry received information related to the study (NCT07599813) titled 'A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis' on May 15.
Brief Summary: This is a phase 2b, multicenter, randomized, double-blind, placebo-controlled study.
Study Start Date: May 15
Study Type: INTERVENTIONAL
Condition:
Atopic Dermatitis
Atopic
Dermatitis
Dermatitis, Atopic
Dermatologic Disease
Eczema
Eczema Atopic Dermatitis
Eczema, Atopic
Intervention:
DRUG: Camoteskimab
Drug Product
DRUG: Placebo
Inactive substance
Recruitment Status: RECRUITING
Sponsor: Apollo Therapeutics Ltd
Published by HT Digital Content Services with permission from Health Daily Digest....